| Drug Name |
Conivaptan hydrochloride |
| Drug ID |
BADD_D00527 |
| Description |
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). |
| Indications and Usage |
For the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients. |
| Marketing Status |
approved; investigational |
| ATC Code |
C03XA02 |
| DrugBank ID |
DB00872
|
| KEGG ID |
D01236
|
| MeSH ID |
C106389
|
| PubChem ID |
216322
|
| TTD Drug ID |
D0VU2X
|
| NDC Product Code |
Not Available |
| UNII |
75L57R6X36
|
| Synonyms |
conivaptan | 4''-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide | (1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)- | YM 087 | YM087 | conivaptan hydrochloride | (1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-, monohydrochloride | Vaprisol |
